中信证券股份有限公司 关于江苏金迪克生物技术股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 中信证券股份有限公司（以下简称 "中信证券"、"保荐人"）作为江苏 金迪克生物技术股份有限公司（以下简称"金迪克"、 "公司"）首次公开发 行人民币普通股（A股）并在科创板上市的保荐人，根据《证券发行上市保荐业 务管理办法》《上海证券交易所科创板股票上市规则》《科创板上市公司持续监 管办法（试行）》《上市公司监管指引第2号—上市公司募集资金管理和使用的 监管要求》及《上海证券交易所上市公司自律监管指引第1号——规范运作》等 有关规定，对金迪克使用部分暂时闲置募集资金进行现金管理的事项进行了核 查，核查情况及核查意见如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意江苏金迪克生物技术股份有限公司首 次公开发行股票注册的批复》（证监许可[2021]1877号）同意，公司采用向社会 公开发行方式发行人民币普通股（A股）22,000,000股，发行价格为每股55.18元， 募集资金总额1,213,960,000.00元，扣除承销费、保荐费、审计费、律师费、信息 披 露 费 等 发 行 费 用 78, ...

江苏金迪克生物技术股份有限公司 内部控制审计报告 江苏金迪克生物技术股份有限公司 内部控制审计报告 （截止 2024 年 12 月 31 日） 政旦志远内字第 2500017 号 政旦志远（深圳）会计师事务所（特殊普通合伙） Zandar Certified Public Accountants LLP 目 录 页 次 一、 内部控制审计报告 1-2 地 址：深圳市福田区鹏程一路广电金融中心11F 电 话：+86-755-88605026 www.zdcpa.com 内 部 控 制 审 计 报 告 政旦志远内字第 2500017 号 江苏金迪克生物技术股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了江苏金迪克生物技术股份有限公司（以下简称江 苏金迪克公司）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策 和程序遵循的程度降低，根据内部控制审计结果推测未来内部控制的 有效性具有一定风险。 第 1 页 政旦 ...

江苏金迪克生物技术股份有限公司 2024 年度独立董事述职报告 作为江苏金迪克生物技术股份有限公司（以下简称"公司"）的独立董事，2024 年度，本人按照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民 共和国证券法》、《上市公司独立董事管理办法》等有关法律法规及《江苏金迪克 生物技术股份有限公司章程》（以下简称"《公司章程》"）、《江苏金迪克生物技术 股份有限公司独立董事工作制度》等相关制度的规范要求，本着对全体股东负责 的态度，忠实、勤勉地履行独立董事职责，积极发挥独立董事的作用，维护公司 和全体股东尤其是中小股东的合法权益。现将 2024 年度履行独立董事职责的具 体情况汇报如下： 一、独立董事的基本情况 （一）2024 年度独立董事变更情况 1 （二）个人工作履历、专业背景及兼职情况 孙红星，女，汉族，1967 年 5 月出生，中国国籍，无境外永久居留权，上海 财经大学会计学院硕士学历，加拿大特许专业会计师。2024 年 1 月至今担任公 司独立董事。现担任上海财经大学会计学院副教授，兼任苏州世名科技股份有限 公司、上海雅运纺织化工股份有限公司独立董事。 （三）是否存在影响独立性的情况说 ...

江苏金迪克生物技术股份有限公司 2024 年度独立董事述职报告 作为江苏金迪克生物技术股份有限公司（以下简称"公司"）的独立董事，2024 年度，本人按照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》《上市公司独立董事管理办法》等有关法律法规及《江苏金迪 克生物技术股份有限公司章程》（以下简称"《公司章程》"）、《江苏金迪克生物 技术股份有限公司独立董事工作制度》等相关制度的规范要求，本着对全体股东 负责的态度，忠实、勤勉地履行独立董事职责，积极发挥独立董事的作用，维护 公司和全体股东尤其是中小股东的合法权益。现将 2024 年度履行独立董事职责 的具体情况汇报如下： 一、独立董事的基本情况 （一）2024 年度独立董事变更情况 公司第二届董事会独立董事为邵蓉女士、管建强先生、程华女士（2024 年 1 月 10 日起不再履职）、孙红星女士（2024 年 1 月 10 日通过股东大会选举）。 2023 年 12 月 6 日，独立董事程华女士因个人原因申请辞去公司独立董事、 第二届董事会审计委员会召集人、第二届董事会薪酬与考核委员会委员职务。因 程华女士的辞职将导致公司独立董事人 ...

江苏金迪克生物技术股份有限公司 独立董事关于公司 2024 年度对外担保情况的 专项说明及独立意见 根据《上市公司独立董事管理办法》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》等有关法律、法规及规范性文件以及《江苏金迪 克生物技术股份有限公司章程》的有关规定和要求，作为江苏金迪克生物技术股 份有限公司(以下简称"公司")的独立董事，我们本着实事求是、认真负责的态度， 对公司 2024 年度对外担保的情况进行了审慎核查，现发表如下专项说明及独立 意见如下： 一、公司对外担保情况 经核查，截至 2024 年 12 月 31 日，公司对外担保余额为 0 元；2024 年度公 司不存在对外担保事项，也无逾期担保事项发生。 二、独立董事发表的独立意见 截至 2024 年 12 月 31 日，公司严格遵守有关法律、法规对担保事项的相关 规定，不存在违规担保行为，严格控制了对外担保风险，不存在损害公司及公司 股东、特别是中小股东利益的情况。 江苏金迪克生物技术股份有限公司 2025 年 4 月 17 日 (本页无正文，为《江苏金迪克生物技术股份有限公司独立董事关于公司 2024 （1799- 独立董 ...

江苏金迪克生物技术股份有限公司 2024 年度独立董事述职报告 作为江苏金迪克生物技术股份有限公司（以下简称"公司"）的独立董事，2024 年度，本人按照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》《上市公司独立董事管理办法》等有关法律法规及《江苏金迪 克生物技术股份有限公司章程》（以下简称"《公司章程》"）、《江苏金迪克生物 技术股份有限公司独立董事工作制度》等相关制度的规范要求，本着对全体股东 负责的态度，忠实、勤勉地履行独立董事职责，积极发挥独立董事的作用，维护 公司和全体股东尤其是中小股东的合法权益。现将 2024 年度履行独立董事职责 的具体情况汇报如下： 一、独立董事的基本情况 （一）2024 年度独立董事变更情况 公司第二届董事会独立董事为邵蓉女士、管建强先生、程华女士（2024 年 1 月 10 日起不再履职）、孙红星女士（2024 年 1 月 10 日通过股东大会选举）。 2023 年 12 月 6 日，独立董事程华女士因个人原因申请辞去公司独立董事、 第二届董事会审计委员会召集人、第二届董事会薪酬与考核委员会委员职务。因 程华女士的辞职将导致公司独立董事人 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥3,463,816.51, a decrease of 30.97% compared to ¥5,018,146.58 in the same period last year[3] - The net profit attributable to shareholders was -¥17,581,346.19, improving from -¥21,490,352.31 year-on-year[3] - Total operating revenue for Q1 2025 was CNY 3,463,816.51, a decrease of 30.7% compared to CNY 5,018,146.58 in Q1 2024[14] - Net loss for Q1 2025 was CNY 17,581,346.19, an improvement from a net loss of CNY 21,490,352.31 in Q1 2024[15] - The company reported a gross profit margin of approximately -515.0% for Q1 2025, compared to -415.0% in Q1 2024[15] Research and Development - Research and development (R&D) expenses totaled ¥7,541,656.25, an increase of 13.37% from ¥6,652,527.57 in the previous year[3] - The ratio of R&D expenses to operating revenue rose to 217.73%, an increase of 85.16 percentage points compared to 132.57% last year[3] - Research and development expenses increased to CNY 7,541,656.25 in Q1 2025, up 135.0% from CNY 3,200,454.60 in Q1 2024[14] Cash Flow and Liquidity - The net cash flow from operating activities was -¥42,060,052.48, slightly better than -¥45,352,501.49 in the same period last year[3] - The company's cash and cash equivalents as of March 31, 2025, amount to ¥112,172,896.19, an increase from ¥83,423,317.41 as of December 31, 2024[10] - The cash inflow from operating activities totaled $15,233,014.78, a decrease of 13.4% compared to $17,593,569.35 in Q1 2024[18] - The cash outflow from operating activities was $57,293,067.26 in Q1 2025, down from $62,946,070.84 in Q1 2024, resulting in a net cash flow from operating activities of -$42,060,052.48[18] - The ending cash and cash equivalents balance for Q1 2025 was $96,372,896.19, an increase from $84,364,559.92 in Q1 2024[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,512,763,341.48, a decrease of 1.31% from ¥1,532,908,768.58 at the end of the previous year[3] - Total current assets decreased to ¥540,968,007.05 from ¥582,580,412.21[11] - Non-current assets totaled ¥971,795,334.43, up from ¥950,328,356.37[11] - Total liabilities decreased to CNY 252,765,889.87 from CNY 255,329,970.78 year-over-year[13] - The company's total equity attributable to shareholders decreased to CNY 1,259,997,451.61 from CNY 1,277,578,797.80 year-over-year[13] Shareholder Information - Total number of common shareholders at the end of the reporting period is 4,258[8] - The top two shareholders, Yu Jun and Zhang Liangbin, each hold 30.74% of the shares, totaling 37,869,008 shares[8] - The company has not reported any significant changes in shareholder relationships or actions during the reporting period[9] Government Support - The company received government subsidies amounting to ¥252,877.51, which had a sustained impact on its profits[5] Operational Insights - The decline in operating revenue was mainly attributed to a decrease in sales volume during the reporting period[6] - There are no significant reminders or additional important information regarding the company's operational situation during the reporting period[10]

Financial Performance - The company reported no cash dividends or stock bonuses for the fiscal year, with retained earnings carried forward to the next year [5]. - The company has not yet achieved profitability since its listing [3]. - The company's operating revenue for 2024 was ¥80,802,661.83, a decrease of 39.96% compared to ¥134,591,377.00 in 2023 [21]. - The net profit attributable to shareholders for 2024 was -¥93,502,830.64, compared to -¥70,990,269.78 in 2023 [21]. - The cash flow from operating activities for 2024 was -¥131,387,331.33, a decline of 262.40% from ¥80,904,692.08 in 2023 [21]. - The company's total assets at the end of 2024 were ¥1,532,908,768.58, down 6.05% from ¥1,631,601,305.25 at the end of 2023 [21]. - The net profit attributable to shareholders of the parent company was -93.50 million yuan, a year-on-year decrease of 31.71% [35]. - The net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was -106.22 million yuan, a year-on-year decrease of 46.37% [35]. - The gross profit margin for the main business was 62.61%, a decrease of 15.20 percentage points compared to the previous year [92]. - The company achieved operating revenue of 80.80 million yuan in the reporting period, a year-on-year decrease of 39.96% [35]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 51.81% in 2024, up 28.43 percentage points from 23.38% in 2023 [22]. - The total R&D investment for the year reached ¥41,862,896.94, an increase of 33.06% compared to the previous year [72]. - The company has established four core technology platforms for vaccine production, covering the entire process of human vaccine research and industrialization [42]. - The company is currently developing 9 major products targeting influenza, rabies, chickenpox, shingles, and pneumonia [76]. - The company has obtained 5 invention patents and 2 utility model patents during the reporting period, enhancing its intellectual property portfolio [65]. - The company is focusing on external collaborations to enhance its R&D capabilities and expand its product pipeline, particularly in the area of new vaccine technologies [60]. - The company has established a comprehensive vaccine R&D and production technology platform, which will support the development of various influenza vaccines and other viral vaccines in the future [63]. - The company is actively conducting preliminary research on adjuvants for influenza vaccines, with plans to initiate development projects based on process research outcomes [36]. - The company has made significant progress in developing a quadrivalent influenza vaccine, with ongoing projects in various clinical stages [76]. - The company aims to complete the pilot-scale process development for all 23 serotypes of the 23-valent pneumococcal polysaccharide vaccine by 2025 [60]. Market and Competitive Landscape - The company plans to leverage the growing market opportunities in China's influenza vaccine sector, which has significant growth potential compared to foreign markets [35]. - The overall vaccination rate for influenza vaccines in China is approximately 3%, significantly lower than the nearly 50% rate in Europe and the US, indicating substantial market growth potential [40]. - The company is accelerating the construction of new production lines for influenza vaccines, which will fundamentally address the long production cycle issue [40]. - The company is focusing on upgrading traditional vaccines and developing innovative vaccines, particularly in the flu vaccine segment, to enhance its competitive advantage [134]. - The company is exploring various sales channels and enhancing customer service to better meet domestic market demands and improve localization capabilities [81]. - The company is actively preparing for GMP inspection of a new production facility to expedite its operational readiness [81]. - The company is considering strategic acquisitions to enhance its product offerings and market presence, with potential targets identified [146]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of $100 million allocated for this purpose [148]. Governance and Compliance - A standard unqualified audit report was issued by the accounting firm for the company [4]. - The board of directors and supervisory board members have confirmed the accuracy and completeness of the annual report [4]. - There are no non-operational fund occupations by controlling shareholders or related parties [7]. - The company has not violated decision-making procedures for external guarantees [7]. - The company has established a governance structure that ensures compliance with relevant laws and regulations, enhancing decision-making efficiency [139]. - The company has established an internal control system, with no significant deficiencies reported during the period [176]. - The company has a governance structure that includes a shareholders' meeting, board of directors, and supervisory board to protect shareholder rights [180]. Environmental and Social Responsibility - The company has invested 1.3326 million RMB in environmental protection measures during the reporting period [184]. - The company has set up a wastewater treatment station to ensure that wastewater discharge meets regulatory standards [182]. - The company actively participates in public health initiatives, donating quadrivalent influenza vaccines to support national health efforts [182]. - The company has implemented effective measures for solid waste management, including hazardous waste disposal by qualified companies [193]. - The company has a dedicated environmental management team responsible for environmental protection and safety production [197]. - The company utilizes rooftop photovoltaic power generation, achieving certain results in energy conservation [196]. - The company has not faced any administrative penalties due to environmental issues during the reporting period [190]. Future Outlook - Future guidance indicates a strong growth trajectory, with expectations of continued revenue increases in the upcoming quarters [147]. - The company plans to expand its market presence and is focusing on new product development to enhance its competitive edge [147]. - The management anticipates a positive impact on user data metrics as a result of new product launches and technological enhancements [200]. - Future outlook includes a commitment to increasing R&D investment to support long-term growth objectives [200]. - The company aims to enhance its core competitiveness in the human vaccine field by increasing R&D investment and focusing on new product development [199]. - The company is committed to sustainability practices as part of its long-term strategic vision [147].

江苏金迪克生物技术股份有限公司董事会 关于独立董事独立性自查情况的专项报告 i . 余 张良斌 聂申钱 军 . 夏建国 都 管建强 费 · ，孙红星 20 5 年 4月17日 in the state 根据证监会《上市公司独立董事管理办法》、《上海证券交易所科创板股票 上市规则》《科创板上市公司自律监管指引第 1 号 -- 规范运作》等要求,江苏 金迪克生物技术股份有限公司(以下简称"公司")董事会,就公司在任独立董事 邵蓉、管建强、孙红星的独立性情况进行评估并出具如下专项意见: 经核查,在任独立董事邵蓉女士、管建强先生、孙红星女士的任职经历以及 签署的相关自查文件,上述人员未在公司担任除独立董事以外的任何职务,也未 在公司主要股东公司担任任何职务,与公司以及主要股东之间不存在利害关系或 其他可能妨碍其进行独立客观判断的关系,因此,公司董事会认为,公司独立董 事符合《上市公司独立董事管理办法》《科创板上市公司自律监管指引第1号-- 规范运作》等规定中对独立董事独立性的相关要求。 江苏金迪 （本页无正文，为《江苏金迪克生物技术股份有限公司董事会关于独立董事独立 性自查情况的专项报告》之签署页） 董事签字: 董事 ...

会计师事务所履职情况评估报告 江苏金迪克生物技术股份有限公司(以下简称"公司")聘请政旦志远(深圳) 会计师事务所(特殊普通合伙)(以下简称"政旦志远")(原名"深圳大华国际会 计师事务所(特殊普通合伙)")为公司 2024 年度财务报告及内部控制审计机构。 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》等规定和要求,公司对 政旦志远在 2024 年度的审计工作的履职情况进行了评估。具体情况如下: 一、2024年年审会计师事务所基本情况 (一) 会计师事务所基本情况 欧旦志远（深圳）会计师事务所（特殊普通合伙）成立于 2005 年 1 月 12 日，注册地址位于深圳市福田区莲花街道福新社区鹏程一路 9 号广电金融中心 11F,首席合伙人为李建伟。 截至 2024 年 12 月 31 日,政旦志远拥有合伙人 29 人,具有中国注册会计师 资格者 91 人，其中，签署过证券服务业务审计报告的注册会计师 68 名。 江苏金迪克生物技术股份有限公司 公司于 2024 年 4 月 15 日召开了第二届董事会第六次会议,第二屈监事会第 六次会议,以 ...